Joanne Lemieux and colleagues say the dipeptide-based protease inhibitor, GC376, and its analog, GC373, should be fast-forwarded for testing in clinical trials of COVID-19. The research is published on the preprint server bioRxiv*.
“They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals (cats),” writes the team. “The work here lays the framework for their use in human trials for the treatment of COVID-19.”
Comments are closed.